Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mylan, a generic pharmaceutical company, has announced that its subsidiary Mylan Pharmaceuticals has received final approval from the FDA for its supplemental abbreviated new drug application for omeprazole delayed-release capsules USP, 40mg, the generic version of AstraZeneca's Prilosec DR capsules.
Subscribe to our email newsletter
Omeprazole delayed-release (DR) capsules are indicated for the treatment of peptic ulcers and gastroesophageal reflux disease. Mylan Pharmaceuticals is shipping this product immediately.